top of page

The Institut Pasteur and Sensorion announce that their partnership to accelerate gene therapy programs targeting hearing disorders has been extended for five years

The framework extension agreement underlines the successful collaboration between Sensorion and the Institut Pasteur, involving the Hearing Institute, a research center of the Institut Pasteur, focused on the development of gene therapy programs.

Two gene therapy development programs are currently being conducted under this agreement, including SENS-501 (OTOF-GT) and GJB2-GT. Sensorion submitted a Clinical Trial Application in July 2023 for SENS-501 to initiate a Phase 1/2 clinical trial in the United Kingdom (UK) and in the European Union (EU).

Professor Christine Petit, Professor at the Hearing Institute, center of the Institut Pasteur, and Professor Emeritus at the Collège de France, France, comments: "I am very satisfied with the progress of the partnership between the Institut Pasteur and Sensorion, and I am delighted that it has been extended. Over the past four years, our teams have achieved major milestones, enabling us to reach the clinical stage with our first gene therapy drug candidate in the field of deafness. We still have many challenges ahead of us to transform these scientific advances into innovations for the benefit of patients, whether in terms of advancing diagnosis and patient care, or developing curative treatments for hearing impairment."

Nawal Ouzren, Sensorion's Chief Executive Officer, adds: "By building on our partnership with the Institut Pasteur and its world-renowned scientific teams, and on the excellence of our development and production know-how, we have achieved, in just four years, a strategic turning point which today positions Sensorion among the leading players in gene therapy applied to hearing disorders. We are convinced that the continuation of the fruitful collaboration between the Institut Pasteur and Sensorion will contribute to the emergence of revolutionary new therapies for thousands of patients suffering from congenital deafness today."

For more information, here is the press release.

Photo credit: Thomas Lang 2017/Institut Pasteur


bottom of page